 | G1 Therapeutics (GTHX) to Release Quarterly Earnings on Wednesday
americanbankingnews.com - July 29 at 9:56 AM |
 | Analysts Estimate G1 THERAPEUTICS (GTHX) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - July 28 at 9:06 PM |
| G1 Therapeutics to Provide Second Quarter 2021 Financial Results and Business Update on August 4, 2021
finance.yahoo.com - July 28 at 11:05 AM |
| G1 Therapeutics, Inc. (NASDAQ:GTHX) Expected to Post Quarterly Sales of $2.70 Million
americanbankingnews.com - July 26 at 2:02 AM |
| Brokerages Expect G1 Therapeutics, Inc. (NASDAQ:GTHX) to Post -$0.96 Earnings Per Share
americanbankingnews.com - July 24 at 7:14 PM |
| Brokerages Anticipate G1 Therapeutics, Inc. (NASDAQ:GTHX) Will Announce Earnings of -$0.96 Per Share
americanbankingnews.com - July 24 at 7:14 PM |
| G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer
finance.yahoo.com - July 19 at 1:28 PM |
| G1 Therapeutics, Inc. (NASDAQ:GTHX) Director Sells $194,500.00 in Stock
americanbankingnews.com - July 15 at 4:44 PM |
|
| G1 Therapeutics, Inc. (NASDAQ:GTHX) Director Mark A. Velleca Sells 10,000 Shares
americanbankingnews.com - July 15 at 4:44 PM |
| G1 Therapeutics (NASDAQ:GTHX) Shares Gap Down After Insider Selling
americanbankingnews.com - July 15 at 10:22 AM |
| Insider Selling: G1 Therapeutics, Inc. (NASDAQ:GTHX) Director Sells 10,000 Shares of Stock
americanbankingnews.com - July 15 at 4:04 AM |
| G1 Therapeutics, Inc. (NASDAQ:GTHX) Receives Average Recommendation of "Buy" from Analysts
americanbankingnews.com - July 11 at 4:12 AM |
| G1 Therapeutics (NASDAQ:GTHX) Shares Gap Up to $20.80
americanbankingnews.com - July 7 at 10:35 AM |
| Rock star Growth Puts G1 Therapeutics (NASDAQ:GTHX) In A Position To Use Debt
finance.yahoo.com - July 6 at 10:56 AM |
| G1 Therapeutics, Inc. (NASDAQ:GTHX) Expected to Post Quarterly Sales of $2.80 Million
americanbankingnews.com - July 5 at 4:08 AM |
| G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors
finance.yahoo.com - June 18 at 1:21 PM |
| G1 Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
finance.yahoo.com - June 16 at 10:07 AM |
 | G1 Therapeutics Starts Mid-Stage Bladder Cancer Trial With Cosela
markets.businessinsider.com - June 15 at 11:34 PM |
| G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer
finance.yahoo.com - June 14 at 8:53 AM |
| G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
finance.yahoo.com - June 4 at 9:08 AM |
| G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer
finance.yahoo.com - June 4 at 9:08 AM |
 | G1 Therapeutics, Inc. Common Stock (GTHX)
nasdaq.com - June 3 at 1:45 PM |
| G1 Therapeutics'(NASDAQ:GTHX) Share Price Is Down 57% Over The Past Three Years.
finance.yahoo.com - May 21 at 12:21 PM |
| G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting
finance.yahoo.com - May 19 at 5:27 PM |
| G1 Therapeutics Presents Two Posters at ISPOR Describing the Estimated Economic Impact of Treating Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer
finance.yahoo.com - May 17 at 7:37 AM |
| G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)
finance.yahoo.com - May 10 at 8:56 AM |
|
 | G1 Therapeutics, Inc. (GTHX) CEO Jack Bailey on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 12:12 AM |
 | G1 Therapeutics, Inc. (GTHX) Q1 2021 Earnings Call Transcript
fool.com - May 6 at 4:34 AM |
| G1 THERAPEUTICS (GTHX) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 5 at 10:02 PM |
| G1 Therapeutics Provides First Quarter 2021 Financial Results and Operational Highlights
finance.yahoo.com - May 5 at 5:01 PM |
| G1 Therapeutics to Provide First Quarter 2021 Financial Results and Business Update on May 5, 2021
finance.yahoo.com - April 28 at 2:40 PM |
| G1 Therapeutics Announces Initiation of Phase 3 Registrational Study of COSELA™ (trilaciclib) in Triple-Negative Breast Cancer (TNBC)
finance.yahoo.com - April 28 at 9:39 AM |
| G1 Therapeutics Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer
finance.yahoo.com - April 26 at 2:10 PM |
| Did G1 Therapeutics' (NASDAQ:GTHX) Share Price Deserve to Gain 69%?
nasdaq.com - April 21 at 9:03 AM |
| G1 Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 7 at 7:31 AM |
| What Kind Of Shareholders Own G1 Therapeutics, Inc. (NASDAQ:GTHX)?
finance.yahoo.com - April 6 at 2:52 PM |
 | G1 Therapeutics to Host Virtual COSELA™ (trilaciclib) Kickoff Analyst and Investor Summit on April 9, 2021
benzinga.com - April 1 at 7:49 AM |
| G1 Therapeutics’ COSELA™ (trilaciclib) Included in Two Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology
finance.yahoo.com - March 25 at 8:05 AM |
| Put Speculative G1 Therapeutics on Your Market Minder Screen
finance.yahoo.com - March 24 at 3:26 PM |
| 'Mad Money' Lightning Round: Peloton, G1 Therapeutics
finance.yahoo.com - March 24 at 10:26 AM |
 | G1 Therapeutics Inc. (NASDAQ: GTHX) Featured in Virtual Coverage of the 33rd Annual ROTH Conference
marketwatch.com - March 17 at 5:37 AM |
| G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - March 5 at 6:28 PM |
| G1 Therapeutics - Brighter Days Ahead
seekingalpha.com - March 4 at 12:05 PM |
| G1 Therapeutics to Participate in Two Investor Conferences in March
finance.yahoo.com - March 3 at 8:36 AM |
| G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
finance.yahoo.com - March 2 at 9:26 AM |
| G1 Therapeutics' (GTHX) CEO Jack Bailey on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - February 26 at 1:26 AM |
| Recap: G1 Therapeutics Q4 Earnings
finance.yahoo.com - February 25 at 12:07 AM |
| G1 Therapeutics, Inc. (GTHX) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 25 at 12:07 AM |
| G1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
finance.yahoo.com - February 24 at 7:06 PM |
| G1 Therapeutics to Provide Fourth Quarter and Full Year 2020 Financial Results and Business Update on February 24, 2021
finance.yahoo.com - February 17 at 8:06 AM |
